1,760 lung adenocarcinoma patient blood samples were tested for analyzing mutations in EGFR, KRAS, NRAS, PIK3CA, HER2, BRAF and MET in cfDNA. This evidence concerns the gene PIK3CA and lung adenocarcinoma.